Fennec Pharmaceuticals
FENC
47 hedge funds and large institutions have $62.2M invested in Fennec Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 8 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
0.83% less ownership
Funds ownership: 50.22% → 49.38% (-0.83%)
2% less funds holding
Funds holding: 48 → 47 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
20% less capital invested
Capital invested by funds: $77.4M → $62.2M (-$15.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$991K |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$582K |
| 3 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$503K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$221K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$524K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$169K |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$148K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$91K |
| 5 |
Goldman Sachs
New York
|
-$86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EWM
51
Edge Wealth Management
New York
| – | -$4K | -502 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$3K | -311 | Closed |
|
|
WSTAM
53
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
| – | -$1K | -100 | Closed |
|
54
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$454 | -65 | -84% |
|
FENC Hedge Fund Activity: Q4 2018 in Review
47 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2018, worth a combined $62.2M — down 20% from $77.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of FENC and 7 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 14 added.
The largest buyer was Granahan Investment Management, adding an estimated $991K. The largest seller was Opaleye Management, cutting an estimated $524K.
- 47 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2018, down from 48 in Q3 2018.
- Funds reported $62.2M of Fennec Pharmaceuticals stock for Q4 2018, down 20% quarter-over-quarter.
- 7 funds opened new Fennec Pharmaceuticals positions in Q4 2018 and 8 closed out, a net change of -1 holder.
- The largest Fennec Pharmaceuticals buyer in Q4 2018 was Granahan Investment Management, an estimated $991K added.
- The largest Fennec Pharmaceuticals seller in Q4 2018 was Opaleye Management, an estimated $524K sold.
Based on aggregated 13F filings for Q4 2018.